Evidence map›Paper›PMID 42024180›Full record

ArticleScience China. Life sciences2026

Artemisinin derivative SM934 targets α-enolase to inhibit PEP-mediated TAK1 stabilization and inflammation.

Jun Pan, Yuwei Zhang, Zhiwei Du, Yuanyuan Huang, Yu Wang, Miya Su, Yuting Cai, Weiya Xu, Lili Chen, Chengdong Huang and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jun PanState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Yuwei ZhangState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Zhiwei DuState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Yuanyuan HuangState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Yu WangState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Miya SuState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Yuting CaiState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Weiya XuInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, 230032, China.
Lili ChenInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, 230032, China.
Chengdong HuangState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Di CuiState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Dongsheng ChenState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Sicheng FuState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Qielan WuState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Chenxi TianState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Maoyu TangInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, 230032, China.
Tuo JiState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Junjie HouInstitute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. houjj_pro@163.com.
Jianping ZuoLaboratory of Immunopharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. jpzuo@mail.shcnc.ac.cn.
Shuhang LiInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, 230032, China. lshhlsy@ustc.edu.cn.
Huimin ZhangState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China. hmzhang@ustc.edu.cn.
Li BaiState Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China. baili@ustc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TGF-β-activated kinase 1 (TAK1) is a key signaling hub and drug target in inflammatory responses. Although metabolism has been critically linked to immune cell function and inflammation, the metabolic control of TAK1 activation and intervention strategy remains to be explored. Here, we show that SM934, a derivative of the traditional Chinese medicine artemisinin, inhibits inflammatory responses via targeting α-enolase and inhibiting metabolite phosphoenolpyruvate (PEP) production. PEP directly binds TAK1 and inhibits its ubiquitination at the lysine-72 site, which promotes NF-κB activation and inflammatory responses. Overall, our study demonstrates a metabolic control of TAK1 stabilization and proposes that it could be disrupted by the derivative of the natural product artemisinin.

Indexed as

ArtemisininsInflammationMAP Kinase Kinase KinasesPhosphopyruvate HydrataseAnimalsHumansMAP Kinase Kinase Kinase 7MiceNF-kappa BSignal TransductionUbiquitinationartemisininArtemisininsMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesNF-kappa BPhosphopyruvate Hydrataseartemisinin derivativeinflammationPEPSM934TAK1α-enolase

Identifiers

PMID42024180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.